How do incretin hormones work?
Incretin hormones (GLP-1 and GIP) are intestinal peptide hormones secreted in response to nutrient intake. They drive glucose-dependent insulin secretion from pancreatic beta cells, contributing to the meal-responsive insulin-release pattern that distinguishes the post-prandial insulin response from the basal-secretion baseline.
What the research literature says
The incretin effect describes the observation that oral glucose produces a larger insulin response than intravenous glucose at matched plasma-glucose concentrations. The differential response is attributed to incretin hormones — GLP-1 (secreted by intestinal L-cells in the distal small intestine) and GIP (secreted by intestinal K-cells in the proximal small intestine) — that are released into circulation in response to nutrient sensing in the gut lumen.
Both incretin hormones engage Class B G-protein-coupled receptors on pancreatic beta cells, signalling through Gαs/cAMP/PKA to enhance glucose-dependent insulin secretion. GLP-1 has additional actions at gastric tissue (slowing gastric emptying) and at central nervous system regions involved in appetite regulation. GIP has additional actions on adipocytes (modulating adipose-tissue lipid metabolism). The Willard tirzepatide pharmacology work characterised the dual-receptor agonism approach (PMID 32730231).
Native GLP-1 and GIP have short plasma half-lives (~2 minutes) due to rapid degradation by dipeptidyl peptidase IV (DPP-IV). Pharmaceutical-class incretin analogues (semaglutide, tirzepatide) are engineered with backbone modifications for DPP-IV resistance plus albumin-binding sidechains for half-life extension — supporting once-weekly subcutaneous dosing with sustained receptor engagement.
Why this matters in research context
Incretin pharmacology matters in peptide-research contexts as the framework underlying the entire modern incretin-receptor-agonist class — semaglutide (single GLP-1 receptor), tirzepatide (dual GIP + GLP-1) (triple GIP + GLP-1 + glucagon). Researchers studying these compounds should account for the integrated incretin-effect biology in interpreting experimental results.
Related compounds
- Semaglutide 10mg — GLP-1 receptor agonist
- Tirzepatide 10mg — dual GIP + GLP-1 agonist
Related research questions
References
- Willard FS et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight 2020;5(17):e140532. [PMID 32730231]
- Sorli C et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1). Lancet Diabetes Endocrinol 2017;5(4):251-260. [PMID 28110911]
- Thomas MK et al. Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes. J Clin Endocrinol Metab 2021;106(2):388-396. [PMID 33236115]
Research-questions pages describe research-context use of peptide-research terminology. They do not constitute medical, veterinary, or clinical advice. Every compound in the Ronin catalog is sold strictly for laboratory and research use only.